STAT 120
A new blood thinning drug is being tested against the current drug in a double-blind experiment. Is there evidence that the mean blood thinness rating is higher for the new drug? Using \(n\) for the new drug and \(o\) for the old drug, which of the following are the null and alternative hypotheses?
A. \(\mathrm{H}_0: \mu_{\mathrm{n}}>\mu_0 \quad\mathrm{Vs}\quad \mathrm{H}_{\mathrm{a}}: \mu_{\mathrm{n}}=\mu_{\mathrm{o}}\)
B. \(\mathrm{H}_0: \mu_{\mathrm{n}}=\mu_0\quad\mathrm{Vs}\quad\mathrm{H}_{\mathrm{a}}: \mu_{\mathrm{n}} \neq \mu_0\)
C. \(\mathrm{H}_0: \mu_{\mathrm{n}}=\mu_0\quad\mathrm{Vs}\quad\mathrm{H}_{\mathrm{a}}: \mu_{\mathrm{n}}>\mu_0\)
D. \(\mathrm{H}_0: \bar{x}_n=\bar{x}_o \quad \mathrm{Vs} \quad \mathrm{H}_{\mathrm{a}}: \bar{x}_n \neq \bar{x}_o\)
E. \(\mathrm{H}_0: \bar{x}_n=\bar{x}_o\quad\mathrm{Vs}\quad\mathrm{H}_{\mathrm{a}}: \bar{x}_n>\bar{x}_o\)
A new blood thinning drug is being tested against the current drug in a double-blind experiment, and the hypotheses are: \[\mathrm{H}_0: \mu_{\mathrm{n}}=\mu_{\mathrm{o}} \quad \text { vS } \quad \mathrm{H}_{\mathrm{a}}: \mu_{\mathrm{n}}>\mu_{\mathrm{o}}\] What does a Type I Error mean in this situation?
A. We reject \(\mathrm{H}_0\)
B. We do not reject \(\mathrm{H}_0\)
C. We find evidence the new drug is better when it is really not better.
D. We are not able to conclude that the new drug is better even though it really is.
E. We are able to conclude that the new drug is better.
A new blood thinning drug is being tested against the current drug in a double-blind experiment, and the hypotheses are: \[\mathrm{H}_0: \mu_{\mathrm{n}}=\mu_{\mathrm{o}} \quad \text { vS } \quad \mathrm{H}_{\mathrm{a}}: \mu_{\mathrm{n}}>\mu_{\mathrm{o}}\]
What does a Type II Error mean in this situation?
A. We reject \(\mathrm{H}_0\)
B. We do not reject \(\mathrm{H}_0\)
C. We find evidence the new drug is better when it is really not better.
D. We are not able to conclude that the new drug is better even though it really is.
E. We are able to conclude that the new drug is better.
A new blood thinning drug is being tested against the current drug in a double-blind experiment, and the hypotheses are: \[\mathrm{H}_0: \mu_{\mathrm{n}}=\mu_{\mathrm{o}} \quad \text { vS } \quad \mathrm{H}_{\mathrm{a}}: \mu_{\mathrm{n}}>\mu_{\mathrm{o}}\]
If the new drug has potentially serious side effects, we should pick a significance level that is:
A. Relatively small (such as \(1 \%\))
B. Middle of the road \((5\%)\)
C. Relatively large (such as \(10 \%\))
Sample Size
Variability
Note: Ensuring a sufficiently large sample and considering the inherent variability in the population are vital in hypothesis testing.
Bootstrap Distribution
Randomization Distribution
Big difference: a randomization distribution assumes \(H_0\) is true, while a bootstrap distribution does not
If a \(95 \%\) CI contains the parameter in \(\mathrm{H}_0\), then a two-tailed test should not reject \(\mathrm{H}_0\) at a \(5 \%\) significance level.
If a \(95 \%\) CI misses the parameter in \(\mathrm{H}_0\), then a two-tailed test should reject \(\mathrm{H}_0\) at a \(5 \%\) significance level.
The 95% confidence interval misses null difference of 0. Reject the null at 5% level
The 99% confidence interval contains null difference of 0. Do not reject the null at 1% level
30:00